# Final Report: Idea 69

## Final ELO Score: 1193.0

## Final Hypothesis

**Title**: Brain-Directed ProTide Riboswitch Agonists Using LAT1 Transporter Targeting

**Key Idea**: Thiamine analogues bearing LAT1-recognised neutral amino-acid promoieties cross the blood–brain barrier, mis-activate pneumococcal TPP riboswitches and treat meningitis.

**Paragraph**: ProTides solved cellular uptake but not BBB entry.  Conjugating an l-phenylalanine ester recruits the LAT1 transporter highly expressed at the BBB, achieving therapeutic CSF levels while sparing peripheral microbiota.

**Approach**: LAT1 in-vitro uptake (hCMEC/D3 cells); in-line probing of riboswitch; rabbit meningitis PK/PD; safety on neuronal cell lines.

**Key References**: Mellin 2015; Howe 2015; Mehellou 2020; NEW—Huttunen & Gynther, Adv. Drug Deliv. Rev., 2022 (LAT1 pro-drugs) [Huttunen 2022].  
Modifications: Added LAT1 targeting for CNS delivery, enhancing translational relevance.

────────────────────────────────────────────────────────
IDEA 34  
────────────────────────────────────────────────────────

## Comprehensive Analysis

This document provides a full analysis of the idea, including its evolution, strengths, weaknesses, and potential applications. Below we trace the development of this idea through each phase of the research process.

## Evolution History

The idea underwent several iterations during the research process:

## Detailed Breakdown

### Title

Brain-Directed ProTide Riboswitch Agonists Using LAT1 Transporter Targeting

### Key Idea

Thiamine analogues bearing LAT1-recognised neutral amino-acid promoieties cross the blood–brain barrier, mis-activate pneumococcal TPP riboswitches and treat meningitis.

### Detailed Explanation

ProTides solved cellular uptake but not BBB entry.  Conjugating an l-phenylalanine ester recruits the LAT1 transporter highly expressed at the BBB, achieving therapeutic CSF levels while sparing peripheral microbiota.

### Implementation Approach

LAT1 in-vitro uptake (hCMEC/D3 cells); in-line probing of riboswitch; rabbit meningitis PK/PD; safety on neuronal cell lines.

### Key References

Mellin 2015; Howe 2015; Mehellou 2020; NEW—Huttunen & Gynther, Adv. Drug Deliv. Rev., 2022 (LAT1 pro-drugs) [Huttunen 2022].  
Modifications: Added LAT1 targeting for CNS delivery, enhancing translational relevance.

────────────────────────────────────────────────────────
IDEA 34  
────────────────────────────────────────────────────────

## Complete Evolution History

This section documents the complete evolution of the idea through each phase of the research process.

### 1. Evolution (Round 4)
**Timestamp:** 2025-05-07 10:43:26



### 2. Reflection (Round 4)
**Timestamp:** 2025-05-07 10:44:53



### 3. Proximity Check (Round 4)
**Timestamp:** 2025-05-07 10:45:31



### 4. Ranking (Round 4)
**Timestamp:** 2025-05-07 10:45:39



### 5. Round Summary (Round 4)
**Timestamp:** 2025-05-07 10:46:18



### 6. Tournament Results
**Timestamp:** 2025-05-07 11:00:51

**ELO Score:** 1193.0



### 7. Final Tournament Results
**Timestamp:** 2025-05-07 11:00:51

**ELO Score:** 1193.0



## Citations

- Huttunen 2022
